Q2 FY2026 EarningsQ2 FY2026 missed consensus expectations across key financial metrics. Revenue was reported at $0 vs. $1.82M expected, reflecting a lack of milestone payments during the quarter. GAAP EPS of -$0.76 was slightly below the -$0.72 consensus due to higher-than-expected R&D and G&A expenses. However, the balance sheet remains strong with $494.9M in cash providing a runway into 2029, while key Phase 2 programs (MZE829 and MZE782) remain on track for clinical milestones through late 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Maze Therapeutics(MAZE) the Revenue is 0 (--%), Miss estimate;the EBIT is -48.04 M (-31.7%), Miss estimate;the EPS is -0.76 (+1.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.00B--
-0.00B--%
EBITMiss expectations
-0.05B31.70%
-0.04B21.03%
-0.00B10.67%
EPSMiss expectations
-0.761.30%
-0.71617.00%
-0.04395.70%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf